Introduction
In 1983 Warren and Marshall' successfully cultured Helicobacter pylori from the stomachs of patients with chronic gastritis. Their discovery has revolutionised our understanding of the pathogenesis and treatment of peptic ulcer disease. Yet despite the passage of 13 years and over 700 publications on eradication therapy, consensus on the optimum treatment for H pylori infection remains elusive.
Antibacterial treatment of H pylori is difficult because of the habitat occupied by the organism below the layer of mucus adherent to the gastric mucosa. It is also difficult because of resistance to antimicrobial agents, especially to nitroimidazoles and increasingly to macrolides, which develops rapidly during treatment, or preexists in the community.2 These factors have led to the concurrent use of several drugs, as exemplified by triple or quadruple regimens. Although these are effective, poor compliance with somewhat complex treatment schedules and adverse effects of the drugs, lessen their efficacy. 3 In 1991 a working party at the World Congress of Gastroenterology in Sydney recommended a triple therapy regimen ('classical' triple therapy) containing bismuth, tetracycline or amoxycillin, and metronidazole: all drugs taken four times daily for two weeks.5 The efficacy of this treatment is highly dependent on the compliance of the patient and the prevalence of pre-treatment metronidazole resistant strains (MRS) of H pylon.6 Classic triple therapy was successful in 90/O of patients with pre-treatment metronidazole sensitive strains (MSS), but in only 30% of patients with MRS, of Hpylori. 6 The combination of omeprazole with either amoxycillin or clarithromycin has been a popular alternative to classic triple therapy, but the reported efficacy of these regimens varies widely,7 and has only moderate efficacy (<80% eradication) in randomised, controlled trials.8-'0 The two week combination of ranitidine bismuth citrate (400 mg twice daily) and clarithromycin (250 mg four times daily) has been reported to eradicate up to 80% of H pylori using an intent to treat analysis." Further studies are awaited using shorter less frequent courses and doses of anti--microbials.
Quadruple regimen consisting of omeprazole 20 mg twice daily (for 10 Three years ago Bazzoli and colleagues'3 reported 100% H pylori eradication in 36 patients using one week, low dose triple therapy regimen containing omeprazole 20 mg once daily, clarithromycin 250 mg and tinidazole 500 mg, twice daily. This regimen was associated with good patient compliance and a low incidence of side effects. Subsequent studies confirmed the efficacy of one week, twice daily combinations of a proton pump inhibitor, clarithromycin and either amoxycillin, or a nitroimidazole (metronidazole or tinidazole); Hpylori eradication was reported in 85-95% of patients.14-'7 However, most of these studies were small (<75 subjects), not randomised, controlled or comparative, and few reported pre-treatment antimicrobial sensitivities of H pylori -important for the determination of efficacy of a treatment containing a nitroimidazole or clarithromycin.
Recent developments
Two large studies of one week, twice daily H pylori eradication regimens were published within the last year.'8 19 The second study, a UK and Eire multicentre, randomised trial, involved 496 H pylori positive patients with duodenal ulcer or non-ulcer gastritis.'`Patients were randomised to either lansoprazole 30 mg plus two of clarithromycin 250 mg, amoxycillin 1 g, metronidazole 400 mg, or to omeprazole 20 mg plus amoxycillin 1 g and metronidazole 400 mg; all given twice daily for one week. Table II shows the results according to an intent to treat analysis.
These two large randomised comparative trials suggest that a one week, low dose twice daily triple therapy regimen containing a proton pump inhibitor with clarithromycin 250-500 mg and either amoxycillin 1 g or metronidazole 400 mg, will cure Hpylori infection in about 90% of patients.
Effect of metronidazole resistance
In the UK and Eire multicentre study pre-treatment H pylori antimicrobial sensitivities were determined on culture of gastric biopsy specimens. The three metronidazole containing regimens were similarly effective in patients with pre-treatment MSS strains of H pylorn, but were significantly (p<005) less effective against MRS of H pylori (Table III) At present, one week, twice daily dose, proton pump inhibitor based triple regimens that comprise a proton pump inhibitor, and two of clarithromycin, a nitromimidazole, or amoxycillin, are being recommended in national and European guidelines. Details of dose still remain to be settled with respect to some of these agents, but these regimens are the current best buy. Direct comparisons of different regimens are very important, but will be difficult to realise, given the constraints ofprevailing funding sources. Efficacy is important, but must be judged in conjunction with other factors, such as ease of compliance, effectiveness against MRS of H pylori, and cost. The available evidence shows that a number of regimens give very similar results, and that suspected or confirmed resistance to nitroimidazoles may, or may not, affect the choice of antimicrobial agents, and perhaps also of the length of treatment. There is still no agreement on whether acid suppression should be continued for a period in all patients after eradication treatment. Perhaps editors of medical journals should attempt to lessen the confusion by carefully considering accretions to the literature pertaining to the treatment of Hpylori, and publishing only well designed and large trials.
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